Theratechnologies Inc T.TH

RE:RE:RE:RE:RE:RE:RE:RE:Soleus holdings

[jfm1330]

One that is on my ignore list is still here.

Wino115 wrote: You are right.  I troll around on a few other sites just as a reader and don't participate. They're really horrible -- almost all are fairly uneducated traders spouting off junk and showing their bravado by posting gains and losses and predicting price levels to the hour. It's some of the market craziness we've all come to see and to dislike.  I would say the majority are traders these days and not investors.  They'll never have the patience to understand actual value creation underlying something that can grow many multiples of your investment.  This site is a rare one where we don't have those pumpers and dumpers and traders like them.  There's a few -- I recall that one poster who actually knew a lot about biotech but he only lasted for 3-4 months and traded it from $2 to $2.50.

jfm1330 wrote: Remember Tanguay's attempt to be more promotional, the 5 to 10 times Egrifta thing. Well, after he was proven wrong on that, he was blamed by some here that are still asking to company to go ahead of facts with rosy promises to push the SP. Sometimes I wonder if some here only want the SP to go higher artificially, just to get out. I am not talking about you since you own so much of it, but smaller investors just look like people wanting an exit point asap.

SPCEO1 wrote: That is normally the situation that helps drive a sahre price higher, but there is loads of evidence that does no longer matters as much as it should. That is crazy but it is also the present reality, which will not last. THTX needs to do all that you mentioned and fiure out a better way to pitch the company to potential retail and institutional investors if the accomplishments they achieve (and have already achieved) are going to translate into a better share price. If nothing else, the last two years should convince even the biggest skeptic that good operational performance is not going to result in a good share price without some additional effort to let the world know what you are doing in an attractive and appealing manner.    

jfm1330 wrote: What is shareholder oriented is good science, success in clinical trials, approvals and commercial success.

Wino115 wrote: Examples like this also point out the value of having venture cap people on your Board.  They are not only a wealth of contacts around the world and in the industry, but are super shareholder oriented.  They add a lot to boards they're on.  Unfortunately, THTX does not have anyone like that on their Board and they can't really tap in to networks like that.  As you can see, it's super valuable for companies in this space. I do think Levesque can get there and likely has plenty of global contacts to lean on once the time comes.  At this point, they need the science to show up first. Then we can talk all sorts of collaborations in regions.

scarlet1967 wrote:

I agree with Palinc moving forward BioAtla  is a phase 1/starting phase 2 cancer company, their CAB ADC programs range are from completed phase 1 to preclinical/ initiating phase 1 ADC programs.

They licensed their BA3071 (a phase 1 ADC program) to BeiGene with offices in China, US, Europe...  and received $25 million in upfront payments & reimbursement, they are also eligible to receive up to $225.5 million for subsequent regulatory and development milestones.

They are in collaboration with Himalaya Therapeutics who has the exclusive license from BioAtla to develop and commercialize several specific CAB candidates for the Greater China, Hong Kong, Macau and Taiwan, including two Phase 1/2 clinical stage assets, as well as worldwide rights to two additional preclinical drug candidates.

They launched IPO on December 16th raising over $217 MM in gross proceeds with $383 million raised to date.

It looks like they have given away the rights of all their ADCs apart from one  entering phase 2.

They are purely R&D, no commercial drugs with a market cap at $1.7 billion. They also seem to have successfully managed to find global partners. I am not sure what their financial assets are as they just launched. To me it shows how a proactive company manages to progress with their R&D programs yet get the attention of bigger biotechs which is the ideal scenario for THTX.

 

Wino115 wrote: One of these was labeled wrong -- it's BioAtla.  This company just went public and has a market cap of $1.6bil.  It's a cancer stock -- they make a biologic that attaches to tumors based on the acidity difference of the membrane and then switches on.  So it's sort of like a homing device that allows for other drugs and vehicles (ADCs, CAR-Ts, others) to just attache to the tumor and not healthy tissues based on "switching" it on. They call them "Conditionally Active Biologics", CABs.

So a way to have much lower toxicity and treat for longer.  Sound familiar?

They're leading drugs are in Phase 2's and target things like sarcoma, ovarian, etc.. The rest is all pre-clinical or about to go Phase 1.  So really, they just have two trials just entering Phase 2 and 3-4 behind that.  Each is a different drug or mechanism attached to their CAB.  

The Soleus guys are on the board.  So lends a bit more to the thought that these guys really do know the cancer space quite well and have chosen to invest in the SORT1+ platform.  Credibility there with that.  I notice the other big holders of BioAtla are Baker Brothers, HRM and assorted other healthcare specialists.  Now they'll have SORT1+ to chat about at their cocktail parties!

Wino115 wrote: I think Spatrap mentioned ESSA PHarma (EPIX) a few weeks ago (prostate cancer drug).  That's one of Soleus larger holdings.  It's up 5x since summer. Others are Biotla (top holding Dec20), Lantheus, Iveric bio, C4 Therapeutics, Alpine Immune. 

Looks like they manage around $700mil in US fund and positions vary from $10-$40mil.